A detailed history of Dafna Capital Management LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Dafna Capital Management LLC holds 486,667 shares of AUTL stock, worth $1.06 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
486,667
Previous 346,667 40.38%
Holding current value
$1.06 Million
Previous $1.21 Million 46.43%
% of portfolio
0.45%
Previous 0.31%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.38 - $4.69 $473,200 - $656,600
140,000 Added 40.38%
486,667 $1.77 Million
Q2 2024

Aug 14, 2024

BUY
$3.33 - $5.68 $432,900 - $738,400
130,000 Added 60.0%
346,667 $1.21 Million
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $137,967 - $186,602
25,597 Added 13.4%
216,667 $1.38 Million
Q4 2023

Feb 14, 2024

SELL
$2.13 - $6.63 $1.57 Million - $4.89 Million
-737,183 Reduced 79.42%
191,070 $1.23 Million
Q3 2023

Nov 14, 2023

SELL
$2.32 - $3.36 $4,967 - $7,193
-2,141 Reduced 0.23%
928,253 $2.16 Million
Q2 2023

Aug 14, 2023

SELL
$1.64 - $3.21 $403,039 - $788,876
-245,756 Reduced 20.89%
930,394 $2.21 Million
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $1.18 Million - $2.22 Million
680,000 Added 137.06%
1,176,150 $2.23 Million
Q1 2022

May 16, 2022

BUY
$3.52 - $5.46 $1.75 Million - $2.71 Million
496,150 New
496,150 $2.07 Million
Q3 2020

Nov 16, 2020

SELL
$11.64 - $16.3 $747,695 - $1.05 Million
-64,235 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$5.38 - $16.14 $836,939 - $2.51 Million
-155,565 Reduced 70.78%
64,235 $1.03 Million
Q1 2020

May 15, 2020

BUY
$4.2 - $13.0 $503,160 - $1.56 Million
119,800 Added 119.8%
219,800 $1.32 Million
Q2 2019

Aug 14, 2019

BUY
$15.1 - $31.25 $1.51 Million - $3.13 Million
100,000 New
100,000 $1.61 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $198M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.